The Collagen Binding Domain of Gelatinase A Modulates Degradation of Collagen IV by Gelatinase B

Journal of Molecular Biology

Volumn 386, Issue 2, 2009, Pages 419-434

  Gioia, Magda ^a,b   Monaco, Susanna ^a,c   Van Den Steen, Philippe E ^d   Sbardella, Diego ^a   Grasso, Giuseppe ^e,f   Marini, Stefano ^a,c   Overall, Christopher M ^b   Opdenakker, Ghislain ^d   Coletta, Massimo ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Interuniversity Consortium for the Research on the Chemistry of Metals in Biological Systems   (Italy)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e UNIVERSITY OF CATANIA   (Italy)

^f CNR   (Italy)

Author keywords

collagen binding domain; gelatinase B; kinetics; matrix metalloproteinases; type IV collagen fragmentation

Indexed keywords

COLLAGEN; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR;

ANALYTIC METHOD; ARTICLE; BINDING SITE; CATALYSIS; CELL MIGRATION; COLLAGEN DEGRADATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; EDMAN SEQUENCING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; NEUTROPHIL; PLACENTA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; SURFACE PLASMON RESONANCE;

EID: 59149094419     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2008.12.021     Document Type: Article

References (64)

1. Overall C.M., and Blobel C.P. In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 8 (2007) 245-257
2. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17 (2001) 463-516
3. Allan J.A., Docherty A.J., Barker P.J., Huskisson N.S., Reynolds J.J., and Murphy G. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem. J. 309 (1995) 299-306
4. Van den Steen P.E., Van Aelst I., Hvidberg V., Piccard H., Fiten P., Jacobsen C., et al. The hemopexin and O-glycosylated domains tune gelatinase B/MMP9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem. 281 (2006) 18626-18637
5. Bachmeier B.E., Iancu C.M., Jocum M., and Nerlich A.G. Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. Exp. Rev. Anticancer Ther. 5 (2005) 149-163
6. Mook O.R., Frederiks W.M., and Van Noorden J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta 1705 (2004) 69-89
7. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grant G.A., and Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J. Biol. Chem. 270 (1995) 5331-5338
8. Seiki M. Membrane-type matrix metalloproteinases. Acta Pathol., Microbiol. Immunol. Scand. 107 (1999) 137-143
9. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., and Quigley J.P. Activation of matrix metalloproteinase-9 (MMP9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274 (1999) 13066-13076
10. Opdenakker G., Van den Steen P.E., and Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 22 (2001) 571-579
11. Robinson S.N., Pisarev V.M., Chavez J.M., Singh R.K., and Talmadge J.E. Use of matrix metalloproteinase MMP9 knockout mice demonstrates that MMP9 activity is not absolutely required for G-CSF or Flt-3 ligand-induced hematopoietic progenitor cell mobilization or engraftment. Stem Cells 21 (2003) 417-427
12. Asahi M., Sumii T., Fini M.E., Itohara S., and Lo E.H. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. NeuroReport 12 (2001) 3003-3007
13. Itoh T., Ikeda T., Gomi H., Nakao S., Suzuki T., and Itohara S. Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J. Biol. Chem. 272 (1997) 22389-22392
14. Leclercq A., Houard X., Philippe M., Ollivier V., Sebbag U., Meilhac O., and Michel J.B. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment. J. Leukocyte Biol. 82 (2007) 1420-1429
15. Reichel C.A., Rehberg M., Bihari P., Moser C.M., Linder S., Khandaga A., and Krombach F. Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodelling. J. Leukocyte Biol. 83 (2008) 864-874
16. Kühn K. Basement membrane (type IV) collagen. Matrix Biol. 14 (1995) 439-445
17. Prockop D.J., and Kivirikko K.I. Collagens: molecular biology, diseases, and potentials for therapy. Annu. Rev. Biochem. 64 (1995) 403-434
18. Dolz R., Engel J., and Kühn K. Folding of collagen IV. Eur. J. Biochem. 178 (1988) 357-366
19. Timpl R., Wiedemann H., van Delden V., Furthmayr H., and Kühn K. A network model for the organization of type IV collagen molecules in basement membranes. Eur. J. Biochem. 120 (1981) 203-211
20. Timpl R. Structure and biological activity of basement membrane proteins. Eur. J. Biochem. 180 (1989) 487-502
21. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit. Rev. Biochem. Mol. Biol. 27 (1992) 93-127
22. Kühn K., Wiedemann H., Timpl R., Risteli J., Dieringer H., Voss T., and Glanville R.W. Macromolecular structure of basement membrane collagens. FEBS Lett. 125 (1981) 123-128
23. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3 (2003) 422-433
24. Hamano Y., Zeisberg M., Sugimoto H., Lively J.C., Maeshima Y., Yang C., et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP9 proteolysis and suppress angiogenesis via alphaVβ3 integrin. Cancer Cell 3 (2003) 589-601
25. Hamano Y., and Kalluri R. Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. Biochem. Biophys. Res. Commun. 29 (2005) 292-298
26. Kamphaus G.D., Colorado P.C., Panka D.J., Hopfer H., Ramchandran R., Torre A., et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275 (2000) 1209-1215
27. Lauer-Fields J.L., Cudic M., Wei S., Mari F., Fields G.B., and Brew K. Engineered sarafotoxins as tissue inhibitor of metalloproteinases-like matrix metalloproteinase inhibitors. J. Biol. Chem. 282 (2007) 26948-26955
28. Lauer-Fields J.L., Whitehead J.K., Li S., Hammer R.P., Brew K., and Fields G.B. Selective modulation of matrix metalloproteinase 9 (MMP9) functions via exosite inhibition. J. Biol. Chem. 283 (2008) 21779-21788
29. Steffensen B., Wallon U.M., and Overall C.M. Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J. Biol. Chem. 270 (1995) 11555-11566
30. Tam E.M., Moore T.R., Butler G.S., and Overall C.M. Characterization of the distinct collagen binding, helicase and cleavage mechanisms of matrix metalloproteinase 2 and 14 (gelatinase A and MT1-MMP): the differential roles of the MMP hemopexin C domains and the MMP2 fibronectin type II modules in collagen triple helicase activities. J. Biol. Chem. 279 (2004) 43336-43344
31. Xu X., Chen Z., Wang Y., Yamada Y., and Steffensen B. Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem. J. 392 (2005) 127-134
32. Xu X., Wang Y., Lauer-Fields J.L., Fields G.B., and Steffensen B. Contributions of the MMP2 collagen binding domains to gelatin cleavage. Substrate binding via the collagen binding domain is required for hydrolysis of gelatin but not short peptides. Matrix Biol. 23 (2004) 171-181
33. Xu X., Chen Z., Wang Y., Bonewald L., and Steffensen B. Inhibition of MMP2 gelatinolysis by targeting exodomain-substrate interactions. Biochem. J. 406 (2007) 147-155
34. Gioia M., Monaco S., Fasciglione G.F., Coletti A., Modesti A., Marini S., and Coletta M. Characterization of the mechanisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP14 recognize collagen I and enzymatically process the two alpha-chains. J. Mol. Biol. 368 (2007) 1101-1113
35. Mackay A.R., Hartzler J.L., Pelina M.D., and Thorgeirsson U.P. Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen. J. Biol. Chem. 265 (1990) 21929-21934
36. Monaco S., Sparano V., Gioia M., Sbardella D., Di Pierro D., Marini S., and Coletta M. Enzymatic processing of collagen IV by MMP2 (gelatinase A) affects neutrophil migration and it is modulated by extracatalytic domains. Protein Sci. 15 (2006) 2805-2815
37. Soininen R., Haka-Risku T., Prockop D.J., and Tryggvason K. Complete primary structure of the alpha-1 chain of human basement membrane (type IV) collagen. FEBS Lett. 225 (1987) 188-194
38. Hostikka S.L.A., and Tryggvason K. Extensive structural differences between genes for the alpha-1 and alpha-2 chains of type IV collagen despite conservation of coding sequences. FEBS Lett. 224 (1987) 297-305
39. Kajimura D., Takahashi S., Yoshikawa K., Hattori S., Sado Y., Imamura Y., and Hayashi T. Non-helical type IV collagen polypeptides in human placenta. Biochem. Biophys. Res. Commun. 314 (2004) 11-16
40. Briknarova K., Gehrmann M., Banyai L., Tordai H., Patthy L., and Llinas M. Gelatin-binding region of human matrix metalloproteinase-2: solution structure, dynamics, and function of the COL-23 two-domain construct. J. Biol. Chem. 276 (2001) 27613-27621
41. Van den Steen P.E., Dubois B., Nelisse I., Rudd P.M., Dwek R.A., and Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP9). Crit. Rev. Biochem. Mol. Biol. 37 (2002) 375-536
42. Ardi V.C., Kupriyanova T.A., Deryugina E.I., and Quigley J.P. Human neutrophils uniquely release TIMP-free MMP9 to provide a potent catalytic stimulator of angiogenesis. Proc. Natl Acad. Sci. USA 104 (2007) 20262-20267
43. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2 (2000) 737-744
44. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., and Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58 (1998) 1048-1051
45. Himelstein B.P., Canete-Soler R., Bernhard E.J., Dilks D.W., and Muschel R.J. Metalloproteinases in tumor progression: the contribution of MMP9. Invasion Metastasis 14 (1994) 246-258
46. Ueda Y., Imai K., Tsuchiya H., Fujimoto N., Nakanishi I., Katsuda S., et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am. J. Pathol. 148 (1996) 611-622
47. Ohashi K., Kawai R., Hara M., Okada Y., Tachibana S., and Ogura Y. Increased matrix metalloproteinases as possible cause of osteoarticular tissue destruction in long-term haemodyalisis and beta 2-microglobulin amyloidosis. Virchows Arch. 428 (1996) 37-46
48. Vidovszky T.J., Cabanela M.E., Rock M.G., Berry D.J., Morrey B.F., and Bolander M.E. Histologic and biochemical differences between osteolytic and nonosteolytic membranes around femoral components of an uncemented total hip arthroplasty. J. Arthroplasty 13 (1998) 320-330
49. Opdenakker G., Nelissen I., and van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2 (2003) 747-756
50. Gutiérrez-Fernández A., Inada M., Balbín M., Fueyo A., Pitiot A.S., Astudillo A., et al. Increased inflammation delays wound healing in mice deficient in collagenase-2 (MMP8). FASEB J. 21 (2007) 2580-2591
51. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J. Clin. Invest. 110 (2002) 625-632
52. Itoh T., Matsuda H., Tanioka M., Kuwabara K., Itohara S., and Suzuki R. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169 (2002) 2643-2647
53. Tanjore H., and Kalluri R. The role of type IV collagen and basement membranes in cancer progression and metastasis. Am. J. Pathol. 168 (2006) 715-717
54. Bányai L., and Patthy L. Evidence for the involvement of type II domains in collagen binding by 72-kDa type IV procollagenase. FEBS Lett. 282 (1991) 23-25
55. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
56. Masure S., Proost P., Van Damme J., and Opdenakker G. Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8. Eur. J. Biochem. 198 (1991) 391-398
57. Laemmlli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
58. Ventzki R., Rüggeberg S., Leicht S., Franz T., and Stegemann J. Comparative 2-DE protein analysis in a 3-D geometry gel. BioTechniques 42 (2007) 271-275
59. Ishihama Y., Rappsilber J., and Mann M. SCX-Stage tip separation using C18-SCX-C18 Stage tip analyzed by LC-MS. J. Proteome Res. 5 (2006) 988-999
60. Knight C.G., Willenbrock F., and Murphy G. A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett. 296 (1992) 263-266
61. Wyman Jr. J. Linked functions and reciprocal effects in hemoglobin: a second look. Adv. Protein Chem. 19 (1964) 223-286
62. Ciaccio, C., Tundo, G.R., Grasso, G., Spoto, G., Marasco, D., Ruvo, M. et al. (2009). Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity. J. Mol. Biol. In the press. doi:10.1016/j.jmb.2008.11.025.
63. Myszka D.G., and Morton T.A. CLAMP: a biosensor kinetic data analysis program. Trends Biochem. Sci. 23 (1998) 149-150
64. Felkel C., Schöll U., Mäder M., Schwartz P., Felgenhauer K., Hardeland R., et al. Migration of human granulocytes through reconstituted basement membrane is not dependent on matrix metalloproteinase-9 (MMP9). J. Neuroimmunol. 116 (2001) 49-55